Handgrip Strength Values Depend on Tumor Entity and Predict 180-Day Mortality in Malnourished Cancer Patients

Pascal Tribolet 1,2,3, Nina Kaegi-Braun 3, Carla Gressies 3, Annic Baumgartner 3, Karl-Heinz Wagner 2, Zeno Stanga 4 and Philipp Schuetz 3,5,*

1 Department of Health Professions, Bern University of Applied Sciences, 3008 Bern, Switzerland; pascal.tribolet@bfh.ch
2 Department of Nutritional Sciences and Research Platform Active Ageing, University of Vienna, 1090 Vienna, Austria; karl-heinz.wagner@univie.ac.at
3 Division of General Internal and Emergency Medicine, Medical University Department, Kantonsspital Aarau, 5001 Aarau, Switzerland; nina.kaegi@ksa.ch (N.K.-B.); carla.gressies@ksa.ch (C.G.); annic.baumgartner@ksa.ch (A.B.)
4 Division of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, 4001 Bern, Switzerland; zeno.stanga@insel.ch
5 Medical Faculty, University of Basel, 4056 Basel, Switzerland
* Correspondence: schuetzph@gmail.com; Tel.: +41-62-838-95-24

Abstract: Background: Cancer-related malnutrition is a prevalent condition associated with a loss of muscle mass and impaired functional status, leading to immunodeficiency, impaired quality of life and adverse clinical outcomes. Handgrip strength (HGS) is a practical measure to assess muscle strength in individual patients during clinical practice. However, HGS reference values refer to populations of healthy people, and population-specific values, such as those in the population of cancer patients, still need to be defined. Methods: Within a secondary analysis of a previous randomized controlled nutritional trial focusing on hospitalized cancer patients at risk for malnutrition, we investigated sex-specific HGS values stratified by age and tumor entity. Additionally, we examined the association between HGS and 180-day all-cause mortality. Results: We included data from 628 cancer patients, which were collected from eight hospitals in Switzerland. Depending on the age of patients, HGS varied among female patients from 7 kg to 26 kg and among male patients from 20.5 kg to 44 kg. An incremental decrease in handgrip strength by 10 kg resulted in a 50% increase in 180-day all-cause mortality (odds ratio 1.52 (95%CI 1.19 to 1.94), p = 0.001). Conclusion: Our data provide evidence of the prognostic implications of HGS measurement in cancer patients and validate the prognostic value of handgrip strength in regard to long-term mortality. In addition, our results provide expected HGS values in the population of hospitalized malnourished cancer patients, which may allow better interpretation of values in individual patients.

Keywords: handgrip strength; malnutrition; cancer; nutritional support; clinical outcomes

1. Introduction

Malnutrition is a highly prevalent condition among oncology patients [1]. Up to 70% of cancer patients are at increased risk for malnutrition [2,3], a condition that is strongly associated with higher mortality and morbidity, functional decline, prolonged hospital stays and increased health care costs [4–9]. The pathophysiology of malnutrition in cancer patients is complex and involves different direct and indirect mechanisms, including inflammation, direct tumor effects, chemotherapy-induced effects and a decrease in appetite [10–12]. In addition, a reduced nutrient intake leads to protein and energy deficits, which in turn lead to muscle wasting and impairment of muscle strength [13,14].

Handgrip strength (HGS) measured through dynamometry is an important tool for the assessment of sarcopenia [15]. HGS has been proposed as an easy-to-use, noninvasive,
Nutrients 2022, 14, 2173

objective and inexpensive tool to detect and monitor changes in nutritional status, and to predict functional decline during hospitalization and post-discharge [16–19]. HGS correlates with nutritional status and may detect changes in functional capacity in an early stage, before changes in the body composition are manifest [20]. Therefore, the use of HGS has been advocated by different international guidelines as an important adjunct in the assessment of malnutrition [21–24]. Moreover, for the population of cancer patients, studies have suggested that lower HGS is associated with higher risks for mortality and sarcopenia, as well as a decrease in quality of life (Qol) [25].

Based on published data of cancer patients, HGS reference values for this population are expected to be lower compared to healthy people [26–30], but there is a lack of data on reference values for this specific patient population. Herein, we investigated sex-specific HGS levels by tumor entity and additionally studied the prognostic information regarding 180-day all-cause mortality and other adverse outcomes from cancer patients included in the Effect of Early Nutritional Support on Frailty, Functional Outcome, and Recovery of Malnourished Medical Inpatients Trial (EFFORT) [31]. Knowledge of such data may provide health care workers with information about expected results when managing cancer patients in their clinical routine.

2. Material and Methods

2.1. Study Design and Setting

This is a secondary analysis of the EFFORT trial, which was a pragmatic, investigator-initiated, open-label, randomized controlled trial conducted in eight Swiss hospitals between April 2014 and February 2018. The original study investigated the effects of a protocol-guided individualized nutritional treatment algorithm on medical outcomes in patients at nutritional risk. The protocol and the main results [31,32], as well as several predefined secondary analyses [33–42], have been previously published. The EFFORT trial was registered with ClinicalTrials.gov, number NCT02517476.

The Ethics Committee of Northwest/Central Switzerland (EKNZ) approved the study protocol in January 2014 (EKNZ; 2014_001). The eight participating sites were secondary and tertiary care hospitals in Switzerland and included the University Clinic in Aarau, the University Hospital in Bern, the cantonal hospitals in Solothurn, Lucerne, St. Gallen, Baselland, Muensterlingen and the hospital in Lachen.

2.2. Patient Population

The methods of the trial have been previously published in detail [31,32]. In brief, for the current analysis, all patients with a cancer diagnosis (wither as the main diagnosis or a comorbidity, or both) from the original trial with available HGS measurements at the time of hospital admission were eligible. EFFORT enrolled consecutive adult patients with a Nutritional Risk Screening 2002 (NRS 2002) [43] total score ≥ 3 points, an expected length of hospital stay (LOS) ≥ 5 days and a willingness to provide informed consent. Patients initially admitted to a surgical unit or intensive care unit were excluded. Other exclusion criteria related to some diseases, including anorexia nervosa, acute pancreatitis, acute liver failure or cystic fibrosis, terminal condition, stem cell transplantation, history of gastric bypass surgery, contraindications for nutritional support, nutritional support at the time of admission and previous inclusion in the trial.

2.3. Assessment and Classification of Handgrip Strength

Grip strength data were collected at the time of admission by trained dieticians with a dynamometer (North Coast Medical Exacta™ Hydraulic Hand Dynamometer, North Coast Medical, Inc., 780 Jarvis Drive, Suite 100, Morgan Hill, CA 95037, USA [44]). The unit of measurement was kg, and measurements were performed in a seated position at the edge of the bed using the dominant hand at a 90° angle position without contacting any surface [45]. The patients performed three attempts, interrupted by a one-minute break, and the highest result was collected.
2.4. Outcomes

For this analysis, the primary endpoint was defined as 180-day all-cause mortality. We prespecified additional short-term and long-term secondary endpoints, including adverse clinical outcomes within 30 days (composite endpoint of the original trial including all-cause mortality, admission to intensive care unit (ICU), 30-day readmission rate, functional decline, length of hospital stay, non-elective hospital readmission and major complications (including nosocomial infection, respiratory failure, a major cardiovascular event and acute renal failure or gastrointestinal failure during hospitalization)) and activities of daily living assessed by Barthel Index. Further long-term secondary outcomes included QoL and incidence of falls during the 180-days follow-up period. QoL was assessed using: (a) the EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D), which ranges from 0 to 1, with higher scores indicating better life quality, and (b) the EQ-5D visual analogue scale (VAS) from 0 to 100, with higher scores indicating better health status.

2.5. Statistical Analysis

Categorical variables are expressed as counts and percentages, and continuous variables as means and standard deviations. We performed descriptive statistics by calculating mean HGS according to tumor entities (hematological tumors, lung cancer, gastrointestinal tumors, prostate carcinoma, breast carcinoma and others (gynecological cancers, kidney and urothelial cancers, ear, nose and throat carcinoma, genital cancer, skin cancer, pleural mesothelioma and cancer of unknown primary and similar)) and age (10-year intervals) stratified by sex.

The association between sex-specific HGS and clinical outcome was investigated using logistic regression analyses for categorical variables with reporting of odd ratios (ORs) and linear regression for continuous variables with reporting of coefficients (Coef) and 95% confidence intervals (CI). We adjusted the results for important confounders (sex, age, weight, height, NRS 2002 score, center), several main diagnoses (cardiovascular, infectious, renal, frailty), various comorbidities (hypertension, chronic kidney disease, chronic heart failure, diabetes mellitus) and for randomization group.

All statistical analyses were performed with STATA 15.1 (Stata Corp, College Station, TX, USA). A \( p \) value < 0.05 (for a 2-sided test) was considered to indicate statistical significance.

3. Results

3.1. Patient Cohort

Of the initial population of 2028 patients included in the original trial recruiting patients from April 2014 to February 2018, we had complete data for 628 (368 male and 260 female) cancer patients from eight hospitals in Switzerland. The baseline characteristics for all patients included in this analysis, stratified according to sex, are shown in Table 1. Patients had a mean age of 72 years (±12.5), and 41.4% were females. The mean (SD) BMI was 24.6 (±4.8) with a similar distribution in both sexes, and the most common admission diagnosis was cancer (50.8%), followed by infection (21.0%). Patients had a high burden of comorbidities, including hypertension (49.8%), chronic renal disease (30.3%), coronary heart disease (24.8%), diabetes mellitus (19.9%) and chronic heart failure (11.6%). The most frequent types of cancer were hematological tumors (19.7%), lung cancer (16.4%), and gastrointestinal tumors (12.4%).

Table 1. Baseline characteristics of malnourished cancer patients.

|                | Overall | Female | Male  |
|----------------|---------|--------|-------|
| \( n \)        | 628     | 260    | 368   |
| Sociodemographic|         |        |       |
| Age (years), mean (SD) | 72.0 (12.5) | 72.3 (11.5) | 71.9 (13.2) |
| Nutritional status|        |        |       |
Table 1. Cont.

|                        | Overall     | Female      | Male        |
|------------------------|-------------|-------------|-------------|
| BMI (kg/m\(^2\)), mean (SD) | 24.6 (4.8)  | 24.6 (5.4)  | 24.6 (4.3)  |
| Weight (kg), mean (SD)  | 70.7 (14.9) | 65.3 (14.0) | 74.4 (14.5) |
| Height (cm), mean (SD)  | 168.6 (8.8) | 162.2 (6.5) | 173.1 (7.2) |
| NRS 3                  | 175 (27.9%) | 72 (27.7%)  | 103 (28.0%) |
| NRS 4                  | 200 (31.8%) | 85 (32.7%)  | 115 (31.3%) |
| NRS 5                  | 253 (40.3%) | 103 (39.6%) | 150 (40.8%) |

Main diagnosis

|                        | Overall     | Female      | Male        |
|------------------------|-------------|-------------|-------------|
| Cancer                 | 319 (50.8%) | 141 (54.2%) | 178 (48.4%) |
| Infection              | 132 (21.0%) | 44 (16.9%)  | 88 (23.9%)  |
| Cardiovascular         | 34 (5.4%)   | 16 (6.2%)   | 18 (4.9%)   |
| Frailty                | 45 (7.2%)   | 21 (8.1%)   | 24 (6.5%)   |
| Lung                   | 22 (3.5%)   | 7 (2.7%)    | 15 (4.1%)   |
| Gastrointestinal       | 29 (4.6%)   | 15 (5.8%)   | 14 (3.8%)   |
| Neurological/psychiatric| 13 (2.1%)  | 5 (1.9%)    | 8 (2.2%)    |
| Renal                  | 11 (1.8%)   | 3 (1.2%)    | 8 (2.2%)    |
| Metabolic              | 6 (1.0%)    | 3 (1.2%)    | 3 (0.8%)    |
| Other                  | 12 (1.9%)   | 4 (1.5%)    | 8 (2.2%)    |

Comorbidities

|                        | Overall     | Female      | Male        |
|------------------------|-------------|-------------|-------------|
| Tumor                  | 580 (92.4%) | 237 (91.2%) | 343 (93.2%) |
| Hypertension           | 313 (49.8%) | 137 (52.7%) | 176 (47.8%) |
| Chronic kidney disease (without kidney replacement therapy) | 190 (30.3%) | 71 (27.3%) | 119 (32.3%) |
| Coronary heart disease | 156 (24.8%) | 47 (18.1%)  | 109 (29.6%) |
| Diabetes mellitus      | 125 (19.9%) | 49 (18.8%)  | 76 (20.7%)  |
| Chronic heart failure  | 73 (11.6%)  | 23 (8.8%)   | 50 (13.6%)  |
| Chronic obstructive pulmonary disease | 70 (11.1%) | 24 (9.2%) | 46 (12.5%) |
| Peripheral arterial vascular disease | 43 (6.8%) | 13 (5.0%) | 30 (8.2%) |
| Stroke                 | 39 (6.2%)   | 10 (3.8%)   | 29 (7.9%)   |
| Dementia               | 14 (2.2%)   | 6 (2.3%)    | 8 (2.2%)    |

Tumor entity

|                        | Overall     | Female      | Male        |
|------------------------|-------------|-------------|-------------|
| Hematological tumors   | 124 (19.7%) | 53 (20.4%)  | 71 (19.3%)  |
| Lung cancer            | 103 (16.4%) | 29 (11.2%)  | 74 (20.1%)  |
| Gastrointestinal tumors| 78 (12.4%)  | 30 (11.5%)  | 48 (13.0%)  |
| Prostate carcinoma     | 62 (9.9%)   | 62 (16.8%)  |             |
| Breast carcinoma       | 56 (8.9%)   | 55 (21.2%)  | 1 (0.3%)    |
| Other *                | 205 (32.6%) | 93 (35.8%)  | 112 (30.4%) |

Handgrip strength (kg), mean (SD)

|                        | Overall HGS | Female      | Male        |
|------------------------|-------------|-------------|-------------|
| Overall HGS            | 23.6 (10.7) | 17.3 (6.3)  | 28.0 (10.8) |

* Gynecological cancers, kidney and urothelial cancers, ear, nose and throat carcinoma, genital cancer, skin cancer, pleural mesothelioma and cancer of unknown primary.
3.2. Handgrip Measurement in the Study Population

The overall mean (SD) HGS was 23.6 (±10.7 kg) with lower values in females (17.3 ± 6.3) compared to males (28.0 ± 10.8). Age, tumor entity and sex-specific HGS data are presented in Table 2. With higher age, the mean (SD) HGS decreased. In younger male cancer patients (<50 years), the mean (SD) HGS was 45.1 kg (±12.7 kg), while in patients ≥ 90 years, there was a mean (SD) HGS of 19.5 kg (±8.0 kg). For female cancer patients, the mean (SD) HGS values were lower, ranging from 23.1 kg (±8.9 kg) in young patients to 8.8 kg (±4.8 kg) in the oldest age group (≥90 years). Stratified by tumor entity, lung cancer patients had the highest mean HGS with 27.4 kg (±10 kg), which was consistent in both sexes (male: mean HGS of 30.8 kg (±9.6 kg), female: mean HGS of 18.9 kg (±4.5 kg)). In the female population, the lowest mean HGS was found in gastrointestinal tumor patients: 16.4 kg (±6.0 kg), whereas male patients had the lowest HGS with prostate carcinoma: 23.6 (±7.4 kg).

Table 2. Handgrip strength according to tumor entity and age.

| Age (year) | Overall (n = 628) | Female (n = 260) | Male (n = 368) |
|-----------|-----------------|-----------------|----------------|
|           | n               | HGS Mean (kg) (SD) | p   | n               | HGS Mean (kg) (SD) | p   | n               | HGS Mean (kg) (SD) | p   |
| <50       | 30              | 38.5 (15.4)      | <0.001 | 21            | 23.1 (8.9)      | <0.001 | 9              | 45.1 (12.7)      | <0.001 |
| 50–59     | 66              | 29.6 (10.3)      |        | 40             | 23.2 (6.0)      |        | 26             | 33.7 (10.5)      |        |
| 60–69     | 119             | 24.4 (9.9)       |        | 66             | 19.0 (6.6)      |        | 53             | 28.8 (10.0)      |        |
| 70–79     | 233             | 23.3 (8.9)       |        | 135            | 17.3 (6.3)      |        | 98             | 27.6 (8.0)       |        |
| 80–89     | 146             | 19.6 (9.2)       |        | 84             | 14.5 (5.3)      |        | 62             | 23.4 (9.6)       |        |
| ≥90       | 34              | 15.7 (8.7)       |        | 22             | 8.8 (4.8)       |        | 12             | 19.5 (8.0)       |        |

Tumor entity

| Hematological tumors | Overall (n = 628) | Female (n = 260) | Male (n = 368) |
|----------------------|-----------------|-----------------|----------------|
|                      | n               | HGS Mean (kg) (SD) | p   | n               | HGS Mean (kg) (SD) | p   | n               | HGS Mean (kg) (SD) | p   |
| Hematological tumors | 124             | 23.1 (11.0)      | <0.001 | 53            | 18.3 (7.0)      | 0.48 | 71             | 26.7 (12.1)      | 0.002 |
| Lung cancer          | 103             | 27.4 (10.0)      |        | 29             | 18.9 (4.5)      |        | 74             | 30.8 (9.6)       |        |
| Gastrointestinal tumors | 78          | 24.1 (11.3)      |        | 30             | 16.4 (6.0)      |        | 48             | 28.9 (11.2)      |        |
| Prostate carcinoma   | 62              | 23.6 (7.4)       |        | -              | -              |        | 62             | 23.6 (7.4)       |        |
| Breast carcinoma     | 56              | 17 (17.4)        |        | 55             | 16.9 (7.4)      |        | 1              | 18              |        |
| Other *              | 205             | 23.7 (11.5)      |        | 93             | 16.9 (7.4)      |        | 112            | 29.3 (11.3)      |        |

Note: Abbreviations: HGS, handgrip strength; SD, standard deviation. * Gynecological cancers, kidney and urothelial cancers, ear, nose and throat carcinoma, genital cancer, skin cancer, pleural mesothelioma and cancer of unknown primary.

3.3. Association of Handgrip with Adverse Outcomes

In a second step, we investigated the prognostic value of HGS in this population of cancer patients stratified by sex (Table 3). In our overall adjusted statistical model, a 10 kg decrease in HGS was associated with a 50% increase in the risk of 180-day all-cause mortality (adjusted OR 1.52 (95% CI 1.19 to 1.94), p = 0.001). The effect was similar among male and female patients, but the association was only significant in male patients (adjusted OR 1.59 (95% CI 1.19 to 2.12), p = 0.002 vs. adjusted OR 1.54 (95% CI 0.89 to 2.65), p = 0.122 for female patients).
Table 3. Association of handgrip strength with short- and long-term outcomes stratified by sex.

|                      | HGS Mean (SD), Patients with No Event | HGS Mean (SD), Patients with Event | HGS Decrease Cont (−10 kg) Unadjusted OR or Coef (95% CI), p-value | * Adjusted OR or Coef (95% CI), p-value |
|----------------------|---------------------------------------|------------------------------------|--------------------------------------------------------------------|----------------------------------------|
| **All patients**     |                                       |                                    |                                                                    |                                        |
| **Primary endpoint** |                                       |                                    |                                                                    |                                        |
| 180-day all-cause mortality | 24.42 (11.13) | 22.35 (9.99) | 1.2 (1.03 to 1.41), \( p = 0.019 \) | 1.52 (1.19 to 1.94), \( p = 0.001 \) |
| **Short-term endpoints (30 days)** | | | | |
| All-cause mortality | 23.81 (10.65) | 22.15 (11.37) | 1.16 (0.92 to 1.48), \( p = 0.211 \) | 1.59 (1.13 to 2.22), \( p = 0.007 \) |
| Adverse outcome | 23.82 (10.73) | 23.17 (10.76) | 1.06 (0.9 to 1.24), \( p = 0.481 \) | 1.23 (0.98 to 1.54), \( p = 0.077 \) |
| Admission to the intensive care unit | 23.71 (10.8) | 19 (6.1) | 1.64 (0.89 to 3.01), \( p = 0.114 \) | 2.58 (1.08 to 6.16), \( p = 0.033 \) |
| Non-elective hospital readmission | 23.42 (10.71) | 25.1 (10.92) | 0.87 (0.7 to 1.08), \( p = 0.211 \) | 0.84 (0.61 to 1.15), \( p = 0.283 \) |
| Any major complication | 23.87 (10.85) | 20.53 (8.84) | 1.39 (1.02 to 1.89), \( p = 0.038 \) | 1.65 (1.09 to 2.51), \( p = 0.018 \) |
| Decline in functional status of ≥10% * | 23.75 (10.5) | 22.93 (11.9) | 1.08 (0.88 to 1.31), \( p = 0.475 \) | 1.18 (0.89 to 1.58), \( p = 0.254 \) |
| Mean length of stay (days) | - | - | 0.22 (−0.29 to 0.73), \( p = 0.398 \) | 0.65 (−0.08 to 1.37), \( p = 0.081 \) |
| Mean Barthel Index score (points) | - | - | −1.69 (−2.48 to −0.9), \( p < 0.001 \) | −1.44 (−2.56 to −0.33), \( p = 0.011 \) |
| **Long-term endpoints (180 days)** | | | | |
| Mean EQ-5D VAS (points) | - | - | −0.81 (−2.87 to 1.25), \( p = 0.442 \) | −1.2 (−4.14 to 1.75), \( p = 0.425 \) |
| Mean EQ-5D index (points) | - | - | −0.02 (−0.03 to 0), \( p = 0.027 \) | −0.01 (−0.03 to 0), \( p = 0.363 \) |
| Incidence of one or more falls | 23.84 (10.69) | 20.37 (10.53) | 1.41 (1.04 to 1.91), \( p = 0.027 \) | 1.58 (1.02 to 2.46), \( p = 0.04 \) |
| **Female patients** | | | | |
| **Primary endpoint** | | | | |
| 180-day all-cause mortality | 18.14 (7.08) | 15.9 (6.31) | 1.62 (1.11 to 2.37), \( p = 0.013 \) | 1.54 (0.89 to 2.65), \( p = 0.122 \) |
| **Short-term endpoints (30 days)** | | | | |
| All-cause mortality | 17.68 (6.79) | 14.33 (7.17) | 2.05 (1.12 to 3.74), \( p = 0.02 \) | 2.26 (1.03 to 4.95), \( p = 0.041 \) |
| Adverse outcome | 17.39 (6.77) | 17.24 (7.22) | 1.03 (0.7 to 1.52), \( p = 0.876 \) | 1.31 (0.8 to 2.15), \( p = 0.275 \) |
| Admission to the intensive care unit | 17.32 (6.94) | 18.43 (4.83) | 0.79 (0.26 to 2.37), \( p = 0.637 \) | 1.33 (0.5 to 3.5), \( p = 0.704 \) |
| Non-elective hospital readmission | 17.05 (6.89) | 19.63 (6.55) | 0.57 (0.32 to 1.01), \( p = 0.055 \) | 0.75 (0.37 to 1.55), \( p = 0.444 \) |
| Any major complication | 17.4 (6.84) | 16.63 (7.59) | 1.18 (0.6 to 2.32), \( p = 0.638 \) | 1.55 (0.67 to 3.57), \( p = 0.304 \) |
Table 3. Cont.

| Decline in functional status of ≥10% | HGS Mean (SD), Patients with No Event | HGS Mean (SD), Patients with Event | HGS Decrease Cont (−10 kg) | HGS Decrease Cont (−10 kg) |
|-------------------------------------|---------------------------------------|-----------------------------------|---------------------------|---------------------------|
|                                     | 17.66 (6.84)                          | 15.51 (6.98)                      | 1.58 (0.95 to 2.62)       | 1.23 (0.64 to 2.39),     |
|                                     |                                       |                                   | p = 0.076                 | p = 0.532                 |
| Mean length of stay (days)          | -                                     | -                                 | 0.33 (−0.88 to 1.53)      | 0.43 (−1.06 to 1.92),     |
|                                     |                                       |                                   | p = 0.596                 | p = 0.569                 |
| Mean Barthel Index score (points)   | -                                     | -                                 | −2.89 (−4.92 to −0.86)    | −2.44 (−4.94 to 0.06),    |
|                                     |                                       |                                   | p = 0.005                 | p = 0.056                 |
| Long-term endpoints (180 days)      |                                       |                                   |                           |                           |
| Mean EQ-5D VAS (points)             | -                                     | -                                 | −2.91 (−7.42 to 1.6)      | −1.47 (−6.89 to 3.95),    |
|                                     |                                       |                                   | p = 0.204                 | p = 0.592                 |
| Mean EQ-5D index (points)           | -                                     | -                                 | −0.05 (−0.09 to −0.01)    | −0.04 (−0.09 to 0.01),    |
|                                     |                                       |                                   | p = 0.013                 | p = 0.084                 |
| Incidence of one or more falls      | 17.59 (6.84)                          | 13.56 (6.13)                      | 2.38 (1.14 to 4.95)       | 3.57 (1.36 to 9.41),      |
|                                     |                                       |                                   | p = 0.021                 | p = 0.01                  |
| Male patients                       |                                       |                                   |                           |                           |
| 180-day all-cause mortality         | 29.33 (11.26)                         | 26.23 (9.79)                      | 1.32 (0.01 to 1.63)       | 1.59 (1.19 to 2.12),      |
|                                     |                                       |                                   | p = 2.69                  | p = 0.002                 |
| Short-term endpoints (30 days)      |                                       |                                   |                           |                           |
| All-cause mortality                 | 28.29 (10.73)                         | 26.38 (11.01)                     | 1.19 (0.25 to 1.61)       | 1.61 (1.09 to 2.38),      |
|                                     |                                       |                                   | p = 1.14                  | p = 0.016                 |
| Adverse outcome                     | 28.54 (10.66)                         | 27 (10.96)                        | 1.15 (0.2 to 1.41)        | 1.18 (0.91 to 1.55),      |
|                                     |                                       |                                   | p = 1.28                  | p = 0.218                 |
| Admission to the intensive care unit| 28.18 (10.77)                         | 19.67 (7.76)                      | 2.77 (0.05 to 7.73)       | 4.28 (0.83 to 22.16),     |
|                                     |                                       |                                   | p = 1.95                  | p = 0.083                 |
| Non-elective hospital readmission   | 27.92 (10.65)                         | 29.02 (11.78)                     | 0.91 (0.53 to 1.22)       | 0.79 (0.54 to 1.15),      |
|                                     |                                       |                                   | p = −0.62                 | p = 0.217                 |
| Any major complication              | 28.47 (10.83)                         | 23.09 (8.77)                      | 1.76 (0.01 to 2.71)       | 1.61 (0.95 to 2.73),      |
|                                     |                                       |                                   | p = 2.58                  | p = 0.08                  |
| Decline in functional status of ≥10%* | 28.24 (10.47)                         | 27.14 (12.09)                     | 1.1 (0.45 to 1.42)        | 1.19 (0.86 to 1.66),      |
|                                     |                                       |                                   | p = 0.76                  | p = 0.297                 |
| Mean length of stay (days)          | -                                     | -                                 | 0.47 (0.17 to 1.15)       | 0.59 (−0.28 to 1.46),     |
|                                     |                                       |                                   | p = 1.38                  | p = 0.182                 |
| Mean Barthel Index score (points)   | -                                     | -                                 | −1.67 (0 to −0.69)        | −0.96 (−2.2 to 0.29),     |
|                                     |                                       |                                   | p = −3.35                 | p = 0.132                 |
| Long-term endpoints (180 days)      |                                       |                                   |                           |                           |
| Mean EQ-5D VAS (points)             | -                                     | -                                 | −1.27 (0.39 to 1.63)      | −0.45 (−4.18 to 3.28),    |
|                                     |                                       |                                   | p = −0.86                 | p = 0.813                 |
| Mean EQ-5D index (points)           | -                                     | -                                 | −0.01 (0.47 to 0.01)      | 0 (−0.03 to 0.02),        |
|                                     |                                       |                                   | p = −0.73                 | p = 0.810                 |
| Incidence of one or more falls      | 28.42 (10.69)                         | 23.78 (10.67)                     | 1.61 (0.02 to 2.37)       | 1.29 (0.78 to 2.11),      |
|                                     |                                       |                                   | p = 2.4                   | p = 0.32                  |

Abbreviations: OR, odds ratio; Coef, coefficient; SD, standard deviation; EQ-5D, EuroQol Group 5-Dimension Self-Report Questionnaire; HGS, handgrip strength; VAS, visual analogue scale. * Adjusted for randomization, age, weight, height, NRS 2002, center, main diagnosis (cardiovascular, infection, renal disease, failure to thrive) and comorbidities (hypertension, chronic kidney failure, chronic heart failure, diabetes mellitus) and for randomization group.
We also found significant associations between HGS and other clinical endpoints, namely 30-day all-cause mortality (adjusted OR 1.59 (95% CI 1.13 to 2.22), \( p = 0.007 \)), admission to ICU (adjusted OR 2.58 (95% CI 1.08 to 6.16), \( p = 0.033 \)), major complications (adjusted OR 1.65 (95% CI 1.09 to 2.51), \( p = 0.018 \)), mean Barthel Index score (points) (adjusted Coef \(-1.44\) (95% CI-2.56 to \(-0.33\), \( p = 0.011 \)) and incidence of one or more falls within 180 days (adjusted OR 1.58 (1.02 to 2.46), \( p = 0.04 \)).

4. Discussion

This secondary analysis of a large, randomized trial found HGS to be highly predictive of long- and short-term mortality and other adverse outcomes among cancer patients. In line with previous research, HGS values depended on sex and patient age [26,27,36], but we additionally found important differences among different types of cancers. Our data provide important HGS reference values for the specific population of cancer patients, which may help future counseling of patients and interpretation of HGS results.

Through the additional stratification by tumor entity, a more precise assessment of functional status and muscle strength via HGS measurements is possible within the population of malnourished cancer patients. It may help to better understand the value of a single HGS measurement in an individual cancer patient and puts this measurement in the perspective of what is expected of the specific population. For this reason, our HGS data from a large, randomized controlled trial may contribute to a better classification of the functional status of malnourished cancer patients by HGS values. Nevertheless, our analysis is still limited by sample size within the different tumor entities, and larger studies would be useful to provide better estimates. Further investigations should also focus on the predictive value of HGS in different tumor entities stratified by age and sex.

Our analysis also showed a significant association of HGS in cancer patients and different clinical outcomes, such as all-cause mortality within 180 days, which is consistent with findings from our research group including other patient populations [36]. In fact, an incremental decrease in HGS by 10 kg resulted in more than doubling the risk for 180-d all-cause mortality among all tumor entities and sexes. These results persisted after adjustment for important cofounders, such as randomization, age, weight, height, NRS 2002, main diagnosis and comorbidities. These findings underline the prognostic value of HGS in malnourished cancer patients and are consistent with results from studies that also included patients with different diseases [36,41,46,47]. Additionally, our results show that, in the overall population, there is a significant association between the Barthel Index score and a decrease in HGS. As both are instruments for assessing functional status, this is an expected result, which was not stable in sex-specific subgroups. A decrease in HGS by 10 kg was also associated with other short-term endpoints, as shown in Table 3.

While the role of nutrition in cancer patients has received little attention, several studies observed a strong increase in mortality in patients with higher nutritional risk [41,48–50]. Indeed, patients with an NRS of \( \geq 5 \) points had a 19% higher risk of long-term mortality compared to those with 3 points in a previous analysis [41]. Our data now suggest that, in addition to clinical information about weight and low appetite included in the NRS score, HGS is an additional parameter that helps providers understand the risk of a patient and may also help with decisions regarding the start of nutritional interventions. Importantly, we recently found that HGS was also predictive for treatment response, with patients in the lowest HGS ranges showing the best response rates [36].

The present analysis has several strengths worth mentioning, including the rather large population of patients with different types of cancer and the prospective gathering of data as part of the EFFORT trial [31,32]. High adherence to the study protocol in the main trial further increases the value of data collected. Limitations include the secondary analysis with limited power and the exploratory nature of our analyses, with the risk for model overfitting and type I error. Validation of our results is thus necessary. Further, we did not include critically ill and surgical cancer patients, which makes our findings only
applicable to medical cancer patients. Since we had only limited information about the CKD stages, we did not consider a further stratification.

5. Conclusions

Our data provide evidence about the prognostic implications of HGS measurement in cancer patients and validate the prognostic value of HGS in regard to long-term mortality. In addition, our results provide expected HGS values in the population of hospitalized malnourished cancer patients, which may allow better interpretation of values in individual patients.

Author Contributions: Conceptualization, P.S., P.T. and N.K.-B.; Methodology, P.S., P.T. and N.K.-B.; Formal Analysis, P.S., P.T. and N.K.-B.; Investigation, P.S., P.T. and N.K.-B.; Data Curation, P.S., P.T. and N.K.-B.; Writing—Original Draft Preparation, P.T., C.G., N.K.-B., A.B., K.-H.W., Z.S. and P.S.; Writing—Review and Editing, P.T., N.K.-B. and C.G.; Visualization, P.S. and K.-H.W.; Project Administration, P.S.; Funding Acquisition, P.S. and Z.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Swiss National Science Foundation (SNSF professorship, PP00P3_150531 and PP00P3_176972) and the Research Council of the Kantonsspital Aarau, Switzerland (1410.000.058 and 1410.000.044).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee Northwest/Central Switzerland (EKNZ) in January 2014 (EKNZ; 2014_001).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgments: We thank all patients and hospital staff for support of our trial.

Conflicts of Interest: Unrelated to this trial, Nestlé Health Science and Abbott Nutrition previously provided unrestricted grant money to the institution of P.S. The institution of Z.S. received research support from Nestlé Health Science, Abbott Nutrition, B. Braun and Fresenius Kabi. All other authors report no conflict of interest.

References

1. Schuetz, P.; Seres, D.; Lobo, D.N.; Gomes, F.; Kaegi-Braun, N.; Stanga, Z. Management of disease-related malnutrition for patients being treated in hospital. Lancet 2021, 398, 1927–1938. [CrossRef]
2. Ryan, A.M.; Power, D.G.; Daly, L.; Cushen, S.J.; Ni Bhuachalla, E.; Prado, C.M. Cancer-associated malnutrition, cachexia and sarcopenia: The skeleton in the hospital closet 40 years later. Proc. Nutr. Soc. 2016, 75, 199–211. [CrossRef] [PubMed]
3. Muscaritoli, M.; Lucia, S.; Farcomeni, A.; Lorusso, V.; Saracino, V.; Barone, C.; Plastino, F.; Gori, S.; Magarotto, R.; Carteni, G.; et al. Prevalence of malnutrition in patients at first medical oncology visit: The PreMiO study. Oncotarget 2017, 8, 79884–79896. [CrossRef] [PubMed]
4. Imoberdorf, R.; Meier, R.; Krebs, P.; Hangartner, P.J.; Hess, B.; Staubli, M.; Wegmann, D.; Ruhlin, M.; Ballmer, P.E. Prevalence of undernutrition on admission to Swiss hospitals. Clin. Nutr. 2010, 29, 38–41. [CrossRef] [PubMed]
5. Felder, S.; Lechtemboeher, C.; Bally, M.; Fehr, R.; Deiss, M.; Faessler, L.; Kutz, A.; Steiner, D.; Rast, A.C.; Laukemann, S.; et al. Association of nutritional risk and adverse medical outcomes across different medical inpatient populations. Nutrition 2015, 31, 1385–1393. [CrossRef] [PubMed]
6. Khalatbari-Soltani, S.; Marques-Vidal, P. The economic cost of hospital malnutrition in Europe; a narrative review. Clin. Nutr. ESPEN 2015, 10, e89–e94. [CrossRef] [PubMed]
7. Planas, M.; Alvarez-Hernandez, J.; Leon-Sanz, M.; Celaya-Perez, S.; Araujo, K.; Garcia de Lorenzo, A.; PREDyCES® Researchers. Prevalence of hospital malnutrition in cancer patients: A sub-analysis of the PREDyCES(R) study. Support. Care Cancer 2016, 24, 429–435. [CrossRef]
8. Lis, C.G.; Gupta, D.; Lammersfeld, C.A.; Markman, M.; Vashi, P.G. Role of nutritional status in predicting quality of life outcomes in cancer—a systematic review of the epidemiological literature. Nutr. J. 2012, 11, 27. [CrossRef]
9. Hebuterne, X.; Lemarie, E.; Michallet, M.; de Montreuil, C.B.; Schneider, S.M.; Goldwasser, F. Prevalence of malnutrition and current use of nutritional support in patients with cancer. J. Parenter. Enter. Nutr. 2014, 38, 196–204. [CrossRef]
10. Anker, S.D.; Laviano, A.; Filippatos, G.; John, M.; Paccagnella, A.; Ponikowski, P.; Schols, A.M.; Espen. ESPEN Guidelines on Parenteral Nutrition: On cardiology and pneumology. Clin. Nutr. 2009, 28, 455–460. [CrossRef]
11. Prado, C.M.; Anker, S.D.; Coats, A.J.S.; Laviano, A.; von Haehling, S. Nutrition in the spotlight in cachexia, sarcopenia and muscle: Avoiding the wildfire. J. Cachexia Sarcopenia Muscle 2021, 12, 3–8. [CrossRef] [PubMed]

12. Bargietzi, L.; Bargietzi, M.; Laviano, A.; Stanga, Z.; Schuetz, P. Inflammation reduces the effect of nutritional therapy on clinical outcomes in cancer patients. Ann. Oncol. 2021, 32, 1451–1452. [CrossRef] [PubMed]

13. Schütz, P.; Bally, M.; Stanga, Z.; Keller, U. Loss of appetite in acutely ill medical inpatients: Physiological response or therapeutic target? Swiss Med. Wkly. 2014, 144, w13957. [CrossRef] [PubMed]

14. Cesaer, M.P.; Van den Bergh, G. Nutrition in the acute phase of critical illness. N. Engl. J. Med. 2014, 370, 1227–1236. [CrossRef]

15. Steenbergh, T.; Averbuch, N.C.; Belin, C.H.S.; Behling, E.B. Hand Grip Strength and nutritional status in hospitalized oncological patients. Rev. Nutr. 2018, 31, 489–499.

16. Humphreys, J.; de la Maza, F.; Hirsch, S.; Barrera, G.; Gattas, V.; Bunout, D. Muscle strength as a predictor of loss of functional status in hospitalized patients. Nutrition 2002, 18, 616–620. [CrossRef]

17. Olguin, T.; Bunout, D.; de la Maza, M.P.; Barrera, G.; Hirsch, S. Admission hand grip strength predicts functional decline in older people: A systematic review and meta-analysis. Ageing Res. Rev. 2019, 51, 48–54. [CrossRef]

18. Nelson, K.; Stobaus, N.; Gonzalez, M.C.; Schulzke, J.D.; Pirlich, M. Hand grip strength: Outcome predictor and marker of nutritional status. Clin. Nutr. 2011, 30, 135–142. [CrossRef]

19. Veronese, N.; Stobaus, N.; Gonzalez, M.C.; Schulzke, J.D.; Pirlich, M. Hand grip strength: Outcome predictor and marker of nutritional status. Clin. Nutr. 2011, 30, 135–142. [CrossRef]

20. Schuetz, P.; Fehr, R.; Baechli, V.; Geiser, M.; Gomes, F.; Kutz, A.; Tribolet, P.; et al. Design and rationale of the effect of early nutritional therapy on frailty, functional outcomes and recovery of malnourished medical inpatients trial (EFFORT): A pragmatic, multicenter, randomized-controlled trial. Int. J. Clin. Trials 2018, 5, 1–9. [CrossRef]

21. Schuetz, P.; Fehr, R.; Baechli, V.; Geiser, M.; Gomes, F.; Kutz, A.; Tribolet, P.; Bregenzer, T.; Hoess, C.; Pavlicek, V.; et al. Hand Grip Strength and Nutritional Variables in Ambulatory Cancer Patients. J. Cachexia Sarcopenia Muscle 2021, 12, 3–8. [CrossRef] [PubMed]

22. Amaral, C.A.; Amaral, T.L.M.; Monteiro, G.T.R.; Vasconcellos, M.T.L.; Portela, M.C. Hand grip strength: Reference values for healthy adult Swiss population. J. Hand Surg. Eur. Vol. 2019, 44, 336–353. [CrossRef]

23. Kilgour, R.D.; Vigan, A.; Trutschnigg, B.; Lucas, E.; Borod, M.; Morais, J.A. Hand grip strength predicts survival and is associated with markers of clinical and functional outcomes in advanced cancer patients. Support. Care Cancer 2013, 21, 3261–3270. [CrossRef]

24. Schuetz, P.; Fehr, R.; Baechli, V.; Geiser, M.; Gomes, F.; Kutz, A.; Tribolet, P.; Bregenzer, T.; Hoess, C.; Pavlicek, V.; et al. Design and rationale of the effect of early nutritional therapy on frailty, functional outcomes and recovery of malnourished medical inpatients trial (EFFORT): A pragmatic, multicenter, randomized-controlled trial. Int. J. Clin. Trials 2018, 5, 1–9. [CrossRef]

25. Merker, M.; Felder, M.; Gueissaz, L.; Bolliger, R.; Tribolet, P.; Kagi-Braun, N.; Gomes, F.; Hoess, C.; Pavlicek, V.; et al. Association of Baseline Inflammation With Effectiveness of Nutritional Support Among Patients With Disease-Related Malnutrition: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw. Open. 2020, 3, e200663. [CrossRef] [PubMed]

26. Bretschera, C.; Boesiger, F.; Kaegi-Braun, N.; Hersberger, L.; Lobo, D.N.; Evans, D.C.; Tribolet, P.; Gomes, F.; Hoess, C.; Pavlicek, V.; et al. Admission serum albumin concentrations and response to nutritional therapy in hospitalised patients at malnutrition risk: Secondary analysis of a randomised clinical trial. EClinicalMedicine 2022, 45, 101301. [CrossRef]

27. Prado, C.M.; Anker, S.D.; Coats, A.J.S.; Laviano, A.; von Haehling, S. Nutrition in the spotlight in cachexia, sarcopenia and muscle: Avoiding the wildfire. J. Cachexia Sarcopenia Muscle 2021, 12, 3–8. [CrossRef] [PubMed]

28. Schuetz, P.; Fehr, R.; Baechli, V.; Geiser, M.; Gomes, F.; Kutz, A.; Tribolet, P.; Bregenzer, T.; Hoess, C.; Pavlicek, V.; et al. Design and rationale of the effect of early nutritional therapy on frailty, functional outcomes and recovery of malnourished medical inpatients trial (EFFORT): A pragmatic, multicenter, randomized-controlled trial. Int. J. Clin. Trials 2018, 5, 1–9. [CrossRef]

29. Gomes, F.; Schuetz, P.; Bounoure, L.; Austin, P.; Ballesteros-Pomar, M.; Cederholm, T.; Fletcher, J.; Laviano, A.; Norman, K.; Pouliá, K.A.; et al. ESPEN guidelines on nutritional support for polymorbid internal medicine patients. Clin. Nutr. 2018, 37, 336–353. [CrossRef]

30. Leong, D.P.; Teo, K.K.; Rangarajan, S.; Kutt, V.R.; Lasans, F.; Hui, C.; Quanyong, X.; Zhenhuan, Q.; Jinhua, T.; Norhaussem, I.; et al. Reference ranges of handgrip strength from 125,462 healthy adults in 21 countries: A prospective urban rural epidemiologic (PURE) study. J. Cachexia Sarcopenia Muscle 2021, 7, 535–546. [CrossRef]

31. Schuetz, P.; Fehr, R.; Baechli, V.; Geiser, M.; Deiss, M.; Gomes, F.; Kutz, A.; Tribolet, P.; Bregenzer, T.; Braun, N.; et al. Individualised nutritional support in medical inpatients at nutritional risk: A randomised clinical trial. Lancet 2019, 393, 2312–2321. [CrossRef]

32. Schuetz, P.; Fehr, R.; Baechli, V.; Geiser, M.; Gomes, F.; Kutz, A.; Tribolet, P.; Bregenzer, T.; Hoess, C.; Pavlicek, V.; et al. Design and rationale of the effect of early nutritional therapy on frailty, functional outcomes and recovery of malnourished medical inpatients trial (EFFORT): A pragmatic, multicenter, randomized-controlled trial. Int. J. Clin. Trials 2018, 5, 1–9. [CrossRef]

33. Merker, M.; Felder, M.; Gueissaz, L.; Bolliger, R.; Tribolet, P.; Kagi-Braun, N.; Gomes, F.; Hoess, C.; Pavlicek, V.; et al. Association of Baseline Inflammation With Effectiveness of Nutritional Support Among Patients With Disease-Related Malnutrition: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw. Open. 2020, 3, e200663. [CrossRef] [PubMed]

34. Breitkroger, C.; Boesiger, F.; Kaegi-Braun, N.; Hersberger, L.; Lobo, D.N.; Evans, D.C.; Tribolet, P.; Gomes, F.; Hoess, C.; Pavlicek, V.; et al. Admission serum albumin concentrations and response to nutritional therapy in hospitalised patients at malnutrition risk: Secondary analysis of a randomised clinical trial. EClinicalMedicine 2022, 45, 101301. [CrossRef]

35. Kaegi-Braun, N.; Tribolet, P.; Gomes, F.; Fehr, R.; Baechli, V.; Geiser, M.; Deiss, M.; Kutz, A.; Bregenzer, T.; Hoess, C.; et al. Six-month outcomes after individualized nutritional support during the hospital stay in medical patients at nutritional risk: Secondary analysis of a prospective randomized trial. Clin. Nutr. 2021, 40, 812–819. [CrossRef] [PubMed]
36. Kaegi-Braun, N.; Tribolet, P.; Baumgartner, A.; Fehr, R.; Baechli, V.; Geiser, M.; Deiss, M.; Gomes, F.; Kutz, A.; Hoess, C.; et al. Value of handgrip strength to predict clinical outcomes and therapeutic response in malnourished medical inpatients: Secondary analysis of a randomized controlled trial. *Am. J. Clin. Nutr.* 2021, 114, 731–740. [CrossRef] [PubMed]

37. Hersberger, L.; Stanga, Z.; Schuetz, P. Reply: The Importance of Objective Nutritional Indexes in Heart Failure Patients. *J. Am. Coll. Cardiol.* 2021, 78, 856–857. [CrossRef]

38. Efthymiou, A.; Hersberger, L.; Reber, E.; Schonenberger, K.A.; Kagi-Braun, N.; Tribolet, P.; Mueller, B.; Schuetz, P.; Stanga, Z.; EFFORT Study Group. Nutritional risk is a predictor for long-term mortality: 5-Year follow-up of the EFFORT trial. *Clin. Nutr.* 2021, 40, 1546–1554. [CrossRef]

39. Baumgartner, A.; Pachnis, D.; Parra, L.; Hersberger, L.; Bargetzi, A.; Bargetzi, L.; Kaegi-Braun, N.; Tribolet, P.; Gomes, F.; Hoess, C.; et al. The impact of nutritional support on malnourished inpatients with aging-related vulnerability. *Nutrition* 2021, 89, 111279. [CrossRef]

40. Baumgartner, A.; Hasenboehler, F.; Cantone, J.; Hersberger, L.; Bargetzi, A.; Bargetzi, L.; Kaegi-Braun, N.; Tribolet, P.; Gomes, F.; Hoess, C.; et al. Effect of nutritional support in patients with lower respiratory tract infection: Secondary analysis of a randomized clinical trial. *Clin. Nutr.* 2021, 40, 1843–1850. [CrossRef]

41. Bargetzi, L.; Brack, C.; Herrmann, J.; Bargetzi, A.; Hersberger, L.; Bargetzi, M.; Kaegi-Braun, N.; Tribolet, P.; Gomes, F.; Hoess, C.; et al. Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: Secondary analysis of a prospective randomized trial. *Ann. Oncol.* 2021, 32, 1025–1033. [CrossRef] [PubMed]

42. Bargetzi, A.; Emmenegger, N.; Wildisen, S.; Nickler, M.; Bargetzi, L.; Hersberger, L.; Segerer, S.; Kagi-Braun, N.; Tribolet, P.; Gomes, F.; et al. Admission kidney function is a strong predictor for the response to nutritional support in patients at nutritional risk. *Clin. Nutr.* 2021, 40, 2762–2771. [CrossRef] [PubMed]

43. Kondrup, J.; Rasmussen, H.H.; Hamberg, O.; Stanga, Z.; An Ad Hoc Espen Working Group. Nutritional risk screening (NRS 2002): A new method based on an analysis of controlled clinical trials. *Clin. Nutr.* 2003, 22, 321–336. [CrossRef]

44. Available online: https://www.ncmedical.com/item_699.html (accessed on 29 April 2020).

45. Bohannon, R.W.; Maljanian, R.; Ferullo, J. Mortality and readmission of the elderly one year after hospitalization for pneumonia. *Aging Clin. Exp. Res.* 2004, 16, 22–25. [CrossRef] [PubMed]

46. Bohannon, R.W. Muscle strength: Clinical and prognostic value of hand-grip dynamometry. *Curr. Opin. Clin. Nutr. Metab. Care* 2015, 18, 465–470. [CrossRef]

47. Sanson, G.; Sadiraj, M.; Barbin, I.; Confezione, C.; De Matteis, D.; Boscutti, G.; Zaccari, M.; Zanetti, M. Prediction of early- and long-term mortality in adult patients acutely admitted to internal medicine: NRS-2002 and beyond. *Clin. Nutr.* 2020, 39, 1092–1100. [CrossRef] [PubMed]

48. Hersberger, L.; Bargetzi, L.; Bargetzi, A.; Tribolet, P.; Fehr, R.; Baechli, V.; Geiser, M.; Deiss, M.; Gomes, F.; Kutz, A.; et al. Nutritional risk screening (NRS 2002) is a strong and modifiable predictor risk score for short-term and long-term clinical outcomes: Secondary analysis of a prospective randomised trial. *Clin. Nutr.* 2020, 39, 2720–2729. [CrossRef]

50. Ravasco, P. Nutrition in Cancer. *Nestle Nutr. Inst. Workshop Ser.* 2015, 82, 91–102. [CrossRef]